A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336

被引:1
|
作者
Carroll, F. Ivy [1 ]
Kosten, Thomas R. [2 ]
Buda, Jeffrey J. [1 ]
Wang, Laurene [3 ]
Walters, Bradford B. [1 ]
机构
[1] RTI Int, Res Triangle Pk, NC 27709 USA
[2] Baylor Coll Med, Psychiat Neurosci Pharmacol & Immunol & Pathol, Houston, TX 77030 USA
[3] INDApharma, Chapel Hill, NC USA
来源
关键词
RTI-336; dopamine transporter inhibitor; Clinical Trials; cocaine dependence; addiction and addiction behaviors; pharmacokinetics and drug metabolism (PDM); safety; tolerability; COCAINE USE DISORDER; DOPAMINE TRANSPORTER; NONHUMAN-PRIMATES; SQUIRREL-MONKEYS; RHESUS-MONKEYS; ABUSE; ANALOGS; DRUGS; PHARMACOTHERAPY; INHIBITORS;
D O I
10.3389/fphar.2018.00712
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Preclinical and clinical data suggest that a compound which binds potently to and inhibits the dopamine transporter, but with a slower onset and offset rate than cocaine and with less abuse potential and psychomotor stimulant activity, could be a useful adjunct in the treatment of cocaine dependence. Methods: We assessed the safety, tolerability, and pharmacokinetics (PK) of oral single doses (0.3, 1, 3, 6, 12, and 20 mg) of such an analog, RTI-336, in a randomized, double-blind, and placebo-controlled trial in healthy adult males. Pre-dose and post-dose safety assessments included physical examinations (including neurological examination); orthostatic vital signs; 6-lead continuous electrocardiogram (ECG) telemetry monitoring pre-dose to 8 h post-dose; 12-lead ECGs; clinical chemistry, hematology, and urinalysis; mini mental status examinations; and adverse events. RTI-336 PK was assessed in plasma and urine. Results: 22 participants were enrolled. RTI-336 was well-tolerated up to the maximum evaluated dose of 20 mg. PK analyses demonstrated good absorption with peak plasma maximum concentrations (C-max) occurring around 4 h post-dose and consistent half-lives of around 17 h for the 6, 12, and 20 mg doses. Plasma drug exposure and Cmax increased in proportion to dose. Only 0.02% of RTI-336 excreted was unchanged in urine. Active metabolites UC-M5, UC-M8, and UC-M2 were measurable in plasma and urine, with plasma Cmax of UC-M5 and UC-M8 exceeding that of RTI-336. Three AE possibly were related to RTI-336 and resolved with discontinuation; the one serious AE was unrelated to RTI-336. 2 participants had transient and mild serum total bilirubin elevations (< 1.5 x upper limit of normal) at day 3 post-dose which resolved by day 8 post-dose. Conclusion: All doses including the highest (20 mg) showed excellent safety and tolerability, and further studies in humans are warranted.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic
    Jeffrey J Buda
    F I Carroll
    Thomas R Kosten
    Dennis Swearingen
    Bradford B Walters
    Neuropsychopharmacology, 2015, 40 : 2059 - 2065
  • [2] A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic
    Buda, Jeffrey J.
    Carroll, F. I.
    Kosten, Thomas R.
    Swearingen, Dennis
    Walters, Bradford B.
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 (09) : 2059 - 2065
  • [3] Pharmacokinetics and Tolerability of Single Escalating Doses of Gabapentin Enacarbil: A Randomized-Sequence, Double-Blind, Placebo-Controlled Crossover Study in Healthy Volunteers
    Lal, Ritu
    Sukbuntherng, Juthamas
    Luo, Wendy
    Chen, Dan
    Vu, Amanda
    Tovera, James
    Cundy, Kenneth C.
    CLINICAL THERAPEUTICS, 2009, 31 (08) : 1776 - 1786
  • [4] Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study
    Li, Yi
    Toyama, Kaoru
    Nakatsu, Takafumi
    Ishizuka, Hitoshi
    Wu, Hailan
    Cao, Guoying
    Yu, Jicheng
    Wang, Yu
    Liu, Xiaofen
    Guo, Beining
    Wu, Jufang
    Yu, Peimin
    Hong, Zhen
    Zhang, Jing
    Wu, Xiaojie
    ADVANCES IN THERAPY, 2023, 40 (04) : 1628 - 1643
  • [5] Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study
    Yi Li
    Kaoru Toyama
    Takafumi Nakatsu
    Hitoshi Ishizuka
    Hailan Wu
    Guoying Cao
    Jicheng Yu
    Yu Wang
    Xiaofen Liu
    Beining Guo
    Jufang Wu
    Peimin Yu
    Zhen Hong
    Jing Zhang
    Xiaojie Wu
    Advances in Therapy, 2023, 40 (4) : 1628 - 1643
  • [6] Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial
    Lisa M. Pitchford
    Patricia M. Driver
    John C. Fuller
    Wendell S. Akers
    Naji N. Abumrad
    Venkataraman Amarnath
    Ginger L. Milne
    Sheau-Chiann Chen
    Fei Ye
    L. Jackson Roberts
    M. Benjamin Shoemaker
    John A. Oates
    John A. Rathmacher
    Olivier Boutaud
    BMC Pharmacology and Toxicology, 21
  • [7] Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial
    Pitchford, Lisa M.
    Driver, Patricia M.
    Fuller, John C., Jr.
    Akers, Wendell S.
    Abumrad, Naji N.
    Amarnath, Venkataraman
    Milne, Ginger L.
    Chen, Sheau-Chiann
    Ye, Fei
    Roberts, L. Jackson, II
    Shoemaker, M. Benjamin
    Oates, John A.
    Rathmacher, John A.
    Boutaud, Olivier
    BMC PHARMACOLOGY & TOXICOLOGY, 2020, 21 (01):
  • [8] Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline
    Newman, Joseph, V
    Zhou, Jian
    Izmailyan, Sergey
    Tsai, Larry
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (11)
  • [9] A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers
    Jansen, Mendel
    Warrington, Steven
    Dishy, Victor
    Ohwada, Shoichi
    Johnson, Lisa
    Brown, Karen
    Ishizuka, Hitoshi
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (06): : 661 - 669
  • [10] Safety, Tolerability, and Pharmacokinetics of β-Cryptoxanthin Supplementation in Healthy Women: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
    Tan, Karen M. L.
    Chee, Jolene
    Lim, Kezlyn L. M.
    Ng, Maisie
    Gong, Min
    Xu, Jia
    Tin, Felicia
    Natarajan, Padmapriya
    Lee, Bee Lan
    Ong, Choon Nam
    Tint, Mya Thway
    Kee, Michelle Z. L.
    Muller-Riemenschneider, Falk
    Gluckman, Peter D.
    Meaney, Michael J.
    Kumar, Mukkesh
    Karnani, Neerja
    Eriksson, Johan G.
    Nandanan, Bindu
    Wyss, Adrian
    Cameron-Smith, David
    NUTRIENTS, 2023, 15 (10)